GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Acutus Medical Inc (OTCPK:AFIB) » Definitions » Sloan Ratio %

Acutus Medical (Acutus Medical) Sloan Ratio % : -132.44% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Acutus Medical Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Acutus Medical's Sloan Ratio for the quarter that ended in Mar. 2024 was -132.44%.

Warning Sign:

When sloan ratio (-142.88)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.

As of Mar. 2024, Acutus Medical has a Sloan Ratio of -132.44%, indicating earnings are more likely to be made up of accruals.


Acutus Medical Sloan Ratio % Historical Data

The historical data trend for Acutus Medical's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acutus Medical Sloan Ratio % Chart

Acutus Medical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
Get a 7-Day Free Trial 27.86 24.42 -21.83 -41.55 -142.88

Acutus Medical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.97 -16.59 -35.85 -142.88 -132.44

Competitive Comparison of Acutus Medical's Sloan Ratio %

For the Medical Devices subindustry, Acutus Medical's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acutus Medical's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Acutus Medical's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Acutus Medical's Sloan Ratio % falls into.



Acutus Medical Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Acutus Medical's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(-81.663--63.118
-58.555)/53.96
=-142.88%

Acutus Medical's Sloan Ratio for the quarter that ended in Mar. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Mar. 2024 )
=(-66.968--64.319
-52.536)/41.668
=-132.44%

Acutus Medical's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was -18.346 (Jun. 2023 ) + -13.237 (Sep. 2023 ) + -33.765 (Dec. 2023 ) + -1.62 (Mar. 2024 ) = $-66.97 Mil.
Acutus Medical's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was -15.369 (Jun. 2023 ) + -14.008 (Sep. 2023 ) + -18.013 (Dec. 2023 ) + -16.929 (Mar. 2024 ) = $-64.32 Mil.
Acutus Medical's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was 15.137 (Jun. 2023 ) + 16.949 (Sep. 2023 ) + 11.22 (Dec. 2023 ) + 9.23 (Mar. 2024 ) = $52.54 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acutus Medical  (OTCPK:AFIB) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Mar. 2024, Acutus Medical has a Sloan Ratio of -132.44%, indicating earnings are more likely to be made up of accruals.


Acutus Medical Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Acutus Medical's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Acutus Medical (Acutus Medical) Business Description

Traded in Other Exchanges
N/A
Address
2210 Faraday Avenue, Suite 100, Carlsbad, CA, USA, 92008
Acutus Medical Inc is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. The company designs, manufactures and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias. Its product portfolio includes Novel access sheaths, Transseptal crossing tools, Diagnostic and mapping catheters, Ablation catheters, Mapping and imaging consoles and accessories, as well as Supporting algorithms and Software programs. It markets and sells its electrophysiology products worldwide to hospitals and electrophysiologists that treat patients with arrhythmias. It has a business presence in the United States and Europe.
Executives
Takeo Mukai officer: Interim CFO C/O ACUTUS MEDICAL, INC., 2210 FARADAY AVE., SUITE 100, CARLSBAD CA 92008
Jason K Garland director 10000 WEHRLE DRIVE, CLARENCE NY 14031
Kevin Mathews officer: SVP, Global Sales C/O ACUTUS MEDICAL, INC., 2210 FARADAY AVE., SUITE 100, CARLSBAD CA 92008
Charlie Piscitello officer: Chief People Officer 2210 FARADAY AVE #100, CARLSBAD CA 92008
Tom Sohn officer: SVP, Gen. Counsel & Secretary 2210 FARADAY AVE #100, CARLSBAD CA 92008
R Scott Huennekens director C/O VOLCANO CORPORATION, 11455 EL CAMINO REAL, SUITE 460, SAN DIEGO CA 92130
James F. Hinrichs director 3750 TORREY VIEW COURT, SAN DIEGO CA 92130
Niamh Louise Pellegrini director C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Orbimed Rof Ii Llc director, 10 percent owner 601 LEXINGTON AVE., 54TH FLOOR, NEW YORK NY 10022
David P Bonita director, 10 percent owner C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
James E Flynn director, 10 percent owner, other: Director by Deputization 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Orbimed Capital Gp Iv Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
John F Sheridan director C/O TANDEM DIABETES CARE, INC., 11045 ROSELLE STREET, SAN DIEGO CA 92121
David Roman officer: SVP & Chief Financial Officer ACUTUS MEDICAL, INC., 2210 FARADAY AVE, SUITE 100, CARLSBAD CA 92008